Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).
Jonathan S. Cebon
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Keith Flaherty
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Jeffrey S. Weber
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Kevin Kim
Research Funding - GlaxoSmithKline
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Adil Daud
No relevant relationships to disclose
Omid Hamid
Research Funding - GlaxoSmithKline
Richard Kefford
Consultant or Advisory Role - GlaxoSmithKline
Lynn Mara Schuchter
Research Funding - GlaxoSmithKline
Jeffrey Alan Sosman
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Bristol-Myers Squibb
Mario Sznol
Consultant or Advisory Role - BeiGene; Bristol-Myers Squibb; Nektar
William Howard Sharfman
Consultant or Advisory Role - Merck
Rene Gonzalez
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Miles Cameron Andrews
No relevant relationships to disclose
Roxana Stefania Dronca
No relevant relationships to disclose
Georgina Long
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche
Honoraria - Roche
Shonda M Little
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Peng Sun
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kiran Patel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Robert R. McWilliams
No relevant relationships to disclose